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PathologyMyotonic dystrophy (DM) is themost common adultmuscular dystrophy, characterized by autosomal dominant
progressive myopathy, myotonia and multiorgan involvement. To date two distinct forms caused by similar
mutations have been identiﬁed. Myotonic dystrophy type 1 (DM1, Steinert's disease) is caused by a (CTG)n
expansion in DMPK, while myotonic dystrophy type 2 (DM2) is caused by a (CCTG)n expansion in ZNF9/CNBP.
When transcribed into CUG/CCUG-containing RNA, mutant transcripts aggregate as nuclear foci that sequester
RNA-binding proteins, resulting in spliceopathy of downstream effector genes. However, it is now clear that
additional pathogenic mechanism like changes in gene expression, protein translation and micro-RNA metabo-
lismmay also contribute to disease pathology. Despite clinical and genetic similarities, DM1 and DM2 are distinct
disorders requiring different diagnostic and management strategies. This review is an update on the recent
advances in the understanding of the molecular mechanisms behind myotonic dystrophies. This article is part
of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Myotonic dystrophies (DMs) are autosomal dominant,multisystemic
diseases with a core pattern of clinical presentation including myotonia,
muscular dystrophy, cardiac conduction defects, posterior iridescent cat-
aracts, and endocrine disorders [1]. In 1909 Steinert and colleagues ﬁrst
clearly described the “classic” type of myotonic dystrophy which was
called Steinert's disease (OMIM 160900). The gene defect responsible
for myotonic dystrophy described by Steinert was discovered in 1992
and found to be caused an expansion of an unstable CTG trinucleotide
repeat in the 3′ untranslated region (UTR) of the myotonic dystrophy
protein kinase gene (DMPK; OMIM 605377) which codes for a myosin
kinase expressed in skeletal muscle. The gene is located on chromosome
19q13.3 [2–4]. Subsequently, in 1994, a different multisystemic disorder
was described with dominantly inherited myotonia, proximal greater
than distal weakness, and cataracts but lacking the gene defect responsi-
ble for Steinert's disease [5–8]. In Europe, the disease was termed proxi-
mal myotonic myopathy (PROMM, OMIM*160900) [5] or proximal
myotonic dystrophy (PDM) [8] while in the United States it was termedscular Diseases: Pathology and
y, University of Milan, IRCCS
ato Mil., Milan, Italy. Tel.: +39
,myotonic dystrophy with no CTG repeat expansion or myotonic dystro-
phy type 2 (DM2) [6]. Later studies demonstrated that many of the fam-
ilies identiﬁed as having myotonic dystrophy type 2, PROMM or PDM
had the same disease, a disorder caused by an unstable tetranucleotide
repeat expansion, CCTG, in intron 1 of the nucleic acid-binding protein
(CNBP) gene (previously known as zinc ﬁnger 9 gene, ZNF9) on chromo-
some 3q21 [9,10]. Due to the existence of different types of myotonic
dystrophy, the InternationalMyotonic Dystrophy Consortium developed
a new nomenclature and guidelines for DNA testing [11]. The Steinert's
disease, the classic form of myotonic dystrophy that results from an un-
stable trinucleotide repeat expansion on chromosome 19, is now termed
myotonic dystrophy type 1 (DM1). Patients with the clinical picture of
myotonic dystrophy type 2/proximal myotonic myopathy, who have
positive DNA testing for the unstable tetranucleotide repeat expansion
on chromosome 3, are now classiﬁed as having myotonic dystrophy
type 2 (DM2) [6,12,13].
Although DM1 and DM2 have similar symptoms, they also present
a number of very dissimilar features making them clearly separate
diseases (Table 1).
2. Clinical features
Myotonic dystrophy type 1 is the most common inherited muscular
dystrophy in adults with an estimated prevalence of 1/8000. Patients
with DM1 can be divided into four main categories, each presenting
speciﬁc clinical features and management problems: congenital,
Table 1
Comparison of clinical manifestations between DM1 and DM2.
Clinical Features DM1 DM2
General features
Epidemiology Widespread European
Age of onset (years) 0 to adult 8–60
Anticipation Always present Exceptional
Congenital form Present Absent
Life expectancy Reduced Normal range
Core features
Clinical myotonia Evident in adult-onset Present in b50%
EMG myotonia Always present Absent or variable in many
Muscle weakness Disabling at age 50 Onset after age 50–70
Cataracts Always present Present in minority
Muscle symptoms
Facial and jaw weakness Always present Usually absent
Bulbar weakness-dysphagia Always later Absent
Respiratory muscles weakness Always later Exceptional
Always prominent Only ﬂexor digitorum profundus, rare
Distal limb muscle weakness May be absent Main disability in most patients, late
Always prominent Prominent in few
Proximal limb muscle weakness Absent or mild Most disabling symptom in many
Sternocleidomastoid weakness Face, temporal, distal hands and legs Usually absent
Myalgic pain Absent Present in ≥50%
Systemic features
Tremors Absent Prominent in many
Behavioral change Early in most Not apparent
Cognitive disorders Prominent Not apparent
Hypersomnia Prominent Infrequent
Cardiac arrhythmias Always present From absent to severe
Male hypogonadism Manifest Subclinical in most
Manifest diabetes Frequent Infrequent
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summarizes these subtypes.
Congenital DM1 (CDM) shows a distinct clinical phenotype with
distinct clinical features therefore it is not to be considered a severe
early form of ‘classical’ DM1. CDM often presents before birth as
polyhydramnios and reduced fetal movements. After delivery, the
main features are severe generalized weakness, hypotonia and respira-
tory compromise. One feature of affected infants is the “ﬁsh-shaped”
upper lip an inverted V-shaped upper lip which is characteristic of
severe facial weakness. Mortality from respiratory failure is high.
Surviving infants experience gradual improvement in motor function,
almost all CDM children are able to walk. Cognitive and motor
milestones are delayed and all patients with CDM develop learning
difﬁculties and require special need schooling. Cerebral atrophy and
ventricular enlargement are often present at birth [14,15]. A progressive
myopathy and the other features seen in the classical form of DM1
can be develop although this does not start until early adulthood andTable 2
Summary of myotonic dystrophy type 1 phenotypes, clinical ﬁndings and CTG length.
Phenotypes Clinical ﬁndings
Congenital Infantile hypotonia
Respiratory failure
Learning disability
Cardiorespiratory complications
Childhood onset Facial weakness
Myotonia
Low IQ
Conduction defects
Adult onset “classic DM1” Weakness
Myotonia
Cataracts
Conduction defects
Insulin resistance
Respiratory failure
Late onset/asymptomatic Mild myotonia
Cataracts
Pre-mutation Noneusually progresses slowly [16]. Clinical myotonia is neither a feature
presented in the neonatal period nor can it be disclosed in the electro-
myogram (EMG). Patients often develop severe problems from cardio-
respiratory complications in their third and fourth decades.
The diagnosis of the DM1 childhood onset form is oftenmissed in af-
fected adolescents or children because of uncharacteristic symptoms for
a muscular dystrophy and apparently negative family history [17].
These patients have cognitive deﬁcits and learning abnormalities [18]
and, as in the congenital cases, degenerative features often develop as
these children reach adulthood. There is increasing evidence of early
heart conduction abnormalities thus annual electrocardiograms and
consideration of electrophysiological studies should be a part of routine
management.
The core features in classic adult-onset DM1 are distal muscle weak-
ness, leading to difﬁculty with performing tasks requiring ﬁne dexterity
of the hands and foot drop, and facial weakness and wasting, giving rise
to ptosis and the typical myopathic or ‘hatchet’ appearance. The neckCTG length Age of onset
N1000 Birth
50–1000 1–10 years
50–1000 10–30 years
50–100 20–70 years
38–49 N/A
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percussion myotonia are regular features; however, myotonia affects
other muscle including bulbar, tongue or facial muscles, causing prob-
lems with talking, chewing, and swallowing. Elevation of the serum
creatine kinase is sometimes present. Cardiac involvement is common
in DM1 and includes conduction abnormalities with arrhythmia and
conduction blocks contributing signiﬁcantly to the morbidity and mor-
tality of the disease [19–22]. In some patients and families, a dilated car-
diomyopathymay be observed. Posterior subcapsular cataracts develop
inmost patients and some patientsmay develop cataract at an early age
without any other symptoms [23]. CNS dysfunctionswith a characteris-
tic of cognitive and neuroimaging involvement are also present [24]
Nocturnal apnoeic episodes and daytime sleepiness are common mani-
festations. Gastrointestinal tract involvement covers irritable bowel
syndrome, symptomatic gall stones and gamma-glutamyltransferase el-
evations. Finally, endocrine abnormalities include testicular atrophy,
hypotestosteronism, and insulin resistance with usually mild type-2
diabetes.
In late-onset or asymptomatic DM1 patients myotonia, weakness
and excessive daytime sleepiness are rarely present. Before DNA tests
became available, there were many examples of incorrect ascertain-
ment, even when using markers such as EMG evidence of myotonia
and slit-lamp examination for the characteristic cataracts [25]. In late-
onset patients, the search for cataracts is helpful for identifying the
transmitting person.
The prevalence of DM2 is not well established, but estimated to be
similar to DM1 in European populations [26]. The most important dis-
crepancy between DM1 and DM2 is the absence of a congenital form
in DM2 [13,27] and the clinical presentation is a more continuum
from early adult-onset severe form to very late-onset mild symptoms
(paucisymptomatic).
Clinically based ascertainment of DM2 patients is even more difﬁcult
because of the large phenotypic variability and a large number of individ-
uals with milder symptoms who remain undiagnosed. Moreover, milder
phenotypes with prominent myalgia may easily be misdiagnosed as
ﬁbromyalgia [28] and patients with the onset of slowly progressive
proximal muscle weakness after the age of 70 years may not be referred
for neuromuscular investigations.
DM2/PROMMtypically appears in adult life and has variablemanifes-
tations, such as early-onset cataracts (younger than 50 years), varying
grip myotonia, thigh muscle stiffness, and muscle pain, as well as weak-
ness [6,13,29–32]. These complaints often appear between 20 and
70 years of age, and patients as well as their care providers ascribe
them to overuse of muscles, “pinched nerves,” “sciatica,” arthritis, ﬁbro-
myalgia, or statin use [33]. Early in the presentation of DM2 there is only
a mild weakness of hip extension, thigh ﬂexion, and ﬁnger ﬂexion. The
myotonia of grip and thighmuscle stiffness varies fromminimal tomod-
erate severity over days to weeks. Myotonia is often less apparent
in DM2 compared with patients with DM1. It is more difﬁcult to elicit
myotonia on standard EMG testing in DM2 compared to DM1 except
for proximal muscles such as the tensor fascia lata and vastus lateralis
muscles. In cases of late-onset DM2, myotonia may only appear on elec-
tromyographic testing after examination of several muscles [30]. The
cataracts in DM2 have an appearance identical to that observed in DM1
and develop before 50 years of age as iridescent, posterior capsular
opacities on slit-lamp. Cardiac problems appear to be less severe and
frequent in patients with DM2 than in patients with DM1 [34–36].
In DM2, cardiac conduction alterations are primarily limited to ﬁrst-
degree atrio-ventricular and bundle branch block. However, sudden
death, pacemaker implantation, and severe cardiac arrhythmias have
been described in small numbers of patients [31,36,37].
Central nervous system involvement represents one of the big issue
and neglected aspect in DM [24]. Although retarded DM2 individuals
have been reported, these occurrences may be either accidental or an
infrequent disease consequence [13,29]. The type of cognitive impair-
ment that occurs in DM2 is similar to but less severe than that ofDM1. Othermanifestations, such as hypogonadism, glucose intolerance,
excessive sweating, and dysphagia, may also occur and worsen over
time in DM2 [6,13,32,38–42]. PDM patients showmany features similar
to those found in PROMM, including proximal muscle weakness, cata-
racts, and electrophysiologically detectable myotonia. Unlike PROMM
patients, however, they do not report myalgias, symptomatic myotonia,
or muscle stiffness. Instead they present traits not present in PROMM,
such as pronounced dystrophic–atrophic changes in the proximal
muscles and late-onset progressive deafness [8].
3. Genetics
In patients affected by DM1 the repeat size range is from 50 to 4.000
(150–12.000 bp) and is nearly always associated with symptomatic dis-
ease although there are patients who have up to 60 repeats who are
asymptomatic into old age and similarly patients with repeat sizes of
up to 500 who are asymptomatic into middle age. Healthy individuals
have between 5 and 37 CTG repeats. Repeat lengths of 38–50 are consid-
ered premutation alleles, whereas 51–100 repeats are protomutations,
both of which show increased instability toward expansion. Patients
with premutations or protomutations are asymptomatic or present few
mild symptoms, such as cataracts, but are at risk of having children
with larger, pathologically expanded repeats [6]. The DM1 mutation
length N2.000 repeats causes the congenital form of the disease [11,43].
In DM1, repeat mutations are dynamic gene defects and show insta-
bility with variation in different tissue and cell types causing somatic
mosaicism [44,45]. The size of the CTG repeat appears to increase over
time in the same individual and across generation. Childrenmay inherit
repeat lengths considerably longer than those present in the transmit-
ting parent. This phenomenon is known as genetic anticipation
in which disease severity increases and/or age of onset of disease
decreases from one generation to the next. A child with congenital
DM1 almost always inherits the expanded mutant DMPK allele from
their mother. However anticipation may be seen in patients with DM1
who inherit a smaller expanded CTG repeat from their father [46,47].
Germ-cell instability is possibly the major determining factor underly-
ing the pronounced anticipation in DM1 [48]. However, the CTG repeat
size does not always increase in successive generations of DM families.
Intergenerational contraction of CTG repeats, a decrease in the CTG
repeat size during transmission from parents to child, can also occur
in about 6.4% of transmissions, most frequently during paternal trans-
missions (10%) [49,50].
In DM1, repeat expansion length is predictive of clinical severity and
age of onset, however, due to somaticmosaicism, CTG repeat size corre-
lates more signiﬁcantly with age of onset and disease severity below
400 CTG repeats [51]. The correlation between CTG repeat size and the
severity of the disease can be observed in blood but not in other organs
(eg,muscle). InDM1 the repeat lengths inmuscle are shown to be larger
[52] and there is no correlation between the size of the CTG repeats in
muscle and the degree of weakness. It should be noted that in clinical
practice, the CTG expansion is measured in blood and there is no addi-
tional clinical advantage of measuring repeat size in muscle.
Recently, DM1 families with expanded alleles with variant repeats
(eg, (CCG)n and (GGC)n repeats, part of the overall (CTG)n repeat
array) have been described [53–56] and in patients with variant repeats
the symptoms are generally less severe than those observed in classical
DM1 [54]. The presence of variant repeats has a dramatic stabilizing ef-
fect on expansion reducing the rate of expansion in affected tissues
leading directly to a delay in the onset and slowing of the progression
of the DM1 symptoms [55]. These observations suggest that interrup-
tions in the primary structure of the CTG expansion could modulate
the clinical phenotype, either by increasing DNA strand stability during
cell divisions, or by producing conformational changes of the variant
RNA species with effects on their toxic gain-of-function. However,
Santoro et al. [56] report that characteristic ribonuclear inclusion
colocalizing with MBNL1 positive foci and splicing defects is observable
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ruptions do not considerably affect the toxic gain of function of expanded
RNAs.
Such variation has been found in up to 4% of unrelated individuals
with DM1 [55] but might have gone undetected in patients presenting
with atypical manifestations. Indeed, variant repeats with extreme GC
contents yield false negatives in both repeat primed PCR and standard
PCR based approaches to diagnostics. For this reason bidirectional trip-
let primed PCR (TP-PCR) should be included in the routine diagnostic
protocol used for DM1 testing since it is very sensitive to detect DM1
expansions presenting variant repeats [57].
DM1 ismost common in populations of European descent, is present
in Japan at about half the frequency, and is rarer still in India [58–60]. To
date only one kindred from sub-Saharan Africa has been described [61].
In contrast to the (CTG)n repeat in DM1, inmyotonic dystrophy type
2 the (CCTG)n repeat is a part of the complex repetitive motif (TG)
n(TCTG)n(CCTG)n. In contrast to the DM1 associated (CTG)n repeat,
the DM2 associated (CCTG)n repeat tract is generally interrupted in
healthy range alleles by one or more GCTG, TCTG or ACTG motifs,
while it is typically uninterrupted in the expanded alleles [10,62,63].
The size of the (CCTG)n repeat is below30 repeats in normal individuals
while the range of expansion sizes in DM2 patients is huge [63]. The
smallest reported mutations vary between 55 and 75 CCTG [10,63]
and the largest expansions have been measured to be up about 11.000
repeats [10]. The expanded DM2 alleles showmarked somatic instabil-
ity, with signiﬁcant increases in length over time [10,13] thus the
threshold size of the disease-causing mutation remains to be deter-
mined. Somatic instability, present in both DM1 and DM2, gives rise to
intra-tissue, inter-tissue, and cell-type variability and somatic mosai-
cismover a patient's lifetime [10,62,64,65]. In DM2 themutation usually
contracts in the next generation being shorter in the children [13]. This
may explain some distinct features of DM2 such as themissing of a con-
genital form, the lack of anticipation and the later onset [27]. The size of
CCTG repeat expansion in leukocyte DNA in DM2 seems to be related in
large part to the age of the patient and not necessarily to the severity of
symptoms or manifestations. This complicates attempts to correlate the
size of the repeat with earlier clinical onset of more severe symptoms as
it occurs in patients with DM1.
Evidence that a large proportion of DM2 patients may be undiag-
nosed came from recent studies which indicate that the co-segregation
of heterozygous recessive CLCN1 mutations in DM2 patients is higher
than expected andmodiﬁes the DM2 phenotype [66,67]. Themutations
of CLCN1 gene, codifying for a skeletal muscle chloride channel (CLC-1),
are responsible of myotonia congenita (recessive Becker disease OMIM
no. 255700; dominant Thomsen disease OMIMno. 160800) and a slight
effect on biophysical proprieties of the chloride channel has been dem-
onstrated in heterozygous recessive mutation [68]. Generally, DM2
affected carriers showed more severe muscle stiffness and more severe
clinical EMG than those having exclusively the CNBP expansion. More
recently, Meola and collaborators (manuscript in preparation) have
identiﬁed the ﬁrst case of a DM2 patient with a concomitant mutation
on SCN4A gene. SCN4A codes for Nav1.4 a voltage gate sodium channel
(VGSC) expressed in muscle [69] and is another gene implicated in
myotonic disorders (Myotonia, Potassium-aggravated OMIM no.
608390). This DM2 patient presented an atypical phenotype character-
ized by early and severemyotonia however nomutation on CLCN1 gene
has been found. Moreover, in this study a novel functional missense
mutation (P72L) on SCN4A gene has been identiﬁed affecting the cyto-
plasmic N terminus domain of Nav1.4. Also in this case the additive ef-
fect of the two mutations may create the atypical severe phenotype
observed in this patient. Thus the CLCN1 or SCN4Amutations may con-
tribute to exaggerating the DM2 phenotype and these patients could be
more easily identiﬁed and diagnosed than DM2 patients without the
modiﬁer allele. Consequently the majority of DM2 patients remain
undiagnosed even in clinical centers with considerable experience
with DM2.To date, DM2 mutations have been identiﬁed predominantly in
European Caucasians and most patients are of northern and eastern
European descent [62,70]. Single kindred of Afghan [32,70] and
Japanese [71] origin have been identiﬁed. It is supposed that both muta-
tions have occurred after migration out of Africa, between 120000 and
60000 years ago [58,72]. Haplotype analysis indicates that the European
DM2 mutations originate from a single founder, between approximately
4000 and 11,000 years ago [62].
4. Molecular pathomechanism
As described above, the two types of the disease are associated with
two different loci: DM1 is caused by the expansion of an unstable CTG
trinucleotide repeat in the 3′ UTR of the DMPK gene [2–4] while DM2
mutation consists in the expansion of an unstable CCTG tetranucleotide
within the ﬁrst intron of CNBP [10]. Although genetically distinct, DM1
and DM2 share a common pathogenic mechanism. Experimental evi-
dence supports anRNA gain-of-functionmechanism inwhich expanded
CUG/CCUG-containing transcripts accumulate in the cell nuclei as foci,
also called ribonuclear inclusions, and are responsible for the pathologic
features common to both disorders. The mutant RNAs form imperfect
double-stranded structure which lead to the deregulation of several
RNA binding factors, including the muscleblind‐like proteins (MBNLs),
CUGBP1, hnRNP H and Staufen1 proteins [73–79]. The MBNL proteins
appear to play a prominent role in DM pathogenesis since each of the
three MBNL isoforms (MBNL1, MBNL2 and MBNL3) are sequestered
by CUG RNAs in the cell nuclei [75,80]. MBNL1 is the most abundant
MBNL protein in adult skeletal muscle and plays the predominant role
in alternative splicing regulation in skeletal and cardiac muscle while
MBNL2, which muscle levels decrease during postnatal development,
serves a related function in the central nervous system [81–83]. Support
for theMBNL loss-of-functionmodel comes fromMbnl1 (Mbnl1ΔE3/ΔE3)
and Mbnl2 (Mbnl2ΔE2/ΔE2) isoform knockout mice which recapitulate
multiple features of adult-onset DM [76,84]. While Mbnl1 knockout
mice develop the muscle, eye, and RNA splicing abnormalities that are
characteristic of DM1 disease and show modest effects on alternative
splicing regulation in the brain [76,85], the loss of Mbnl2 leads to wide-
spread changes in postnatal splicing patterns in the brain, many of
which are similarly dysregulated in the human DM1 brain, but not in
skeletal muscle [82]. Nothing is known about the functions of MBNL3
in vivo, although this protein is also sequestered by toxic CUG exp
RNAs [80]. In vitro studies show that MBNL3 acts as an antagonist of
myogenesis possibly by maintaining myoblasts in a proliferative state
[86–88]. Mbnl3 isoform knockout mice show age-dependent impair-
ment of adult muscle regeneration suggesting that Mbnl3 inhibition
by toxic RNA expressionmay be a contributing factor to the progressive
skeletal muscle weakness and wasting characteristic of DM [88].
CUGBP1, a member of the family of CELF (CUGBP, Elav-like family)
proteins, is a regulator of alternative splicing and of mRNA translation
and stability [89–93]. CUGBP1 does not colocalize with ribonuclear
foci in DM1 cells [75,80,94], however this protein was identiﬁed
through its capacity to bind CUG RNA repeats in vitro [95]. CUGBP1
may have a role in the pathogenesis of splicing abnormalities because
it is overexpressed in DM1myoblasts, skeletal muscle and heart tissues
[40,96,97] due to PKC-mediated hyperphosphorylation and subsequent
protein stabilization and upregulation [98]. While it is clear that MBNL1
is depleted from nucleoplasm through recruitment into ribonuclear in-
clusions both in DM1 and DM2 even when clinical symptoms and mus-
cle alterations are very mild [67,99–102], CUGBP1 overexpression has
been clearly demonstrated in DM1 but not in DM2 muscle biopsies. In
a recent work on the expression of CUGBP1 in human skeletal muscle
from DM1 and DM2 patients, Cardani et al. [103] demonstrate that
this protein is overexpressed in muscle biopsies from patients affected
by the adult classical form of DM1 but not in muscle from DM2 patients
suggesting that sequestration of MBNL1 evidently has a central role in
splicing misregulation in both types of DM while in DM1 CUGBP1
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shared by DM2. Besides its nuclear role in splicing, CUGBP1 also has
other functions in the cytoplasm where it regulates mRNA translation
and stability [89,92,93]. The alterations of protein [92] and mRNA
[104] levels occur in DM1 consistentwith the idea that the perturbation
of CUGBP1 cytoplasmic functions contributes to DM1 pathogenesis.
CUGBP1 cellular localization depends on its phosphorylation status
[91]. The activation of the Akt pathway increases CUGBP1 phosphoryla-
tion at Ser-28 altering the transition from proliferating myoblasts to
differentiated myotubes in DM1 [105]. On the other hand, DM1 cells
show decreased activity of cyclin D3-cdk4, another kinase that phos-
phorylates CUGBP1. This renders higher levels of unphosphorylated
CUGBP1, which forms inactive complexes with eIF2a (CUGBP1-eIF2a)
affecting translation of mRNAs required for myoblast differentiation.
These inactive complexes containing CUGBP1 accumulate in the cyto-
plasm of DM1 cells in stress granules [91]. CUGBP1-eIF2a complex has
been found also in the cytoplasm of DM2 myoblasts [106].
Other splicing factors involved in early phases of pre-mRNA process-
ing, beside MBNLs and CUGBP1 proteins, have been found to be altered
in DMpathologies. An elevation of the steady-state level of hnRNPHhas
been observed in DM1 myoblasts while recent data demonstrate that
MBNL1-containing foci in DM2 cells also sequester snRNPs and hnRNPs.
These data strengthen the hypothesis that a general alteration of pre-
mRNA post-transcriptional pathway could be at the basis of the multi-
factorial phenotype of DM patients [78,107,108]. Staufen1 is another
regulator of alternative splicing that has been involved in DM1 patholo-
gy [79]. As CUGBP1, this protein is not sequestered by nuclear foci of
CUGexp mRNAs but it has been found to be markedly and speciﬁcally
increased in skeletal muscle from DM1 mouse models and patients.
Interesting, Staufen1 up-regulation might have a protective role in the
DM1 pathology since it appears that the increase in Staufen1 may
indeed be a compensatory mechanism used by muscle ﬁbers to reduce
and/or delay the detrimental effects caused by MBNL1 sequestration
and CUGBP1 up-regulation [79].
Thus, themisregulation of alternative splicing caused by the deregu-
lation of several splicing regulators clearly plays a central role in the
development of important DM symptoms [109,110]. Among the symp-
toms of DM, myotonia, insulin resistance and cardiac problems are cor-
related with the disruption of the alternative splicing of the muscle
chloride channel ClC-1, of the insulin receptor (IR) and of the cardiac
troponin T (TNNT3), respectively [40,42,74,111,112]. More recently,
muscle weakness has been associated with bridging integrator 1
(BIN1) missplicing both in DM1 and DM2. BIN1 is a lipid-binding
protein that is involved in the biogenesis of the T tubule network in
muscle and in the regulation of the excitation–contraction coupling
[113]. However, there is no direct evidence of a cause–effect relation-
ship between symptoms and missplicing and it is now clear that
spliceopathymay not fully explain the multisystemic disease spectrum.
Bachinski and collaborators [114] performed global array-based expres-
sion and splicing proﬁling on a large number of DMand non-DMneuro-
muscular patients and found that DM1 and DM2 skeletal muscles were
essentially identical to each other for both expression and splicing.
Moreover, most expression and splicing changes were shared between
multiple muscular dystrophies, as previously reported [115,116]. This
suggests that splicing changes may be a much more general phenome-
non of muscle disease and can be secondary to muscle regeneration
[115,116].
Studies performed on different DM animal models suggest that
splicing, RNA foci, and muscle pathology are separable events [76,
117–119] and strongly suggest that DM molecular pathogenesis may
be vastly more complex involving changes in gene expression and
translation efﬁciency, non-conventional translation and micro-RNA
(miRNA) deregulation.
Various studies reported the effects of repeat expansion on gene ex-
pression in DM1 and DM2muscle biopsies indicating common proﬁles,
suggestive of a mutual pathophysiology [120–123]. Altered geneexpression may also result from a direct effect of the repeat expansion
on transcription factors. The binding of mutant RNA in DM1 causes
inappropriate redistribution (leaching) of various transcription factors,
such as Sp1 and RARγ, reducing their availability and the expression
of target transcripts [124]. Changes to the levels of a panel of RNAs
involved in muscle development and function that are downregulated
in DM1 have been associated to aberrant localization in the cytoplasm
of DM1 myoblasts of the transcription factor SHARP (SMART/HDAC1-
associated repressor protein) [125].
A novel molecular mechanism that may contribute to the pathogen-
esis of several diseases including myotonic dystrophies has been de-
scribed in a recent paper by Ranum's group [126]. RNA transcripts
containing expanded CAG repeats can be translated in the absence of
a starting ATG and this non-canonical translation, called Repeat Associ-
ated Non-ATG translation (RAN-translation) occurs across expanded
CAG repeats in all reading frames (CAG, AGC, and GCA) to produce
homopolymeric proteins of long polyglutamine, polyserine, and
polyalanine tracts [126]. RAN translation across human spinocerebellar
ataxia type 8 (SCA8) andmyotonic dystrophy type 1 (DM1) CAGexpan-
sion transcripts results in the accumulation of SCA8 polyalanine and
DM1 polyglutamine expansion proteins in previously established
SCA8 and DM1 mouse models and human tissue [126]. Antibodies
developed speciﬁcally against DM1 polyGln proteins, detect polyGln
nuclear aggregates in DM1 mouse tissues and DM1 patient cardiac
myocytes, leukocytes, and myoblasts not detectable in control tissues.
RAN-translation products appear to be toxic to cells andmay contribute
to DM1 pathology. More recently RAN translation has been found to
occur across intronic DM2 CCUG transcripts and that these transcripts
produce a tetra-repeat expansion protein with a repeating Leu-Pro-
Ala-Cys (LPAC) motif. Moreover an LPAC antibody shows strong immu-
nostaining in human DM2 autopsy brain but not controls. Immuno-
staining has been observed in neurons, astrocytes and glia in frontal
cortex, hippocampus and basal ganglia. These data suggest that RAN
translation may be common to both DM1 and DM2 and that RAN
proteins may be responsible for some of the CNS features of DM [127].
miRNAs are small non-coding RNA modulating gene expression at
posttranscriptional level and their expression and intracellular distribu-
tion are deregulated in many human diseases, including muscular dys-
trophies [128–132]. Both in DM1 and DM2 it has been demonstrated
that the highly regulated pathways of miRNA is altered in skeletal
muscle potentially contributing to DM pathogenetic mechanisms
[130–132]. Themisregulation of miR-1 observed in the hearts of people
with DM1 and DM2 may contribute to the cardiac dysfunctions ob-
served in affected persons [133]. The signiﬁcant reduction of miR-1 in
DM cardiac muscle appears to be caused by the expression of expanded
CUG repeats and subsequent MBNL1 nuclear sequestration [133]. Inter-
estingly, Perfetti et al. [134] identify a signature ofmiRNAderegulated in
peripheral blood plasma from DM1 patients. In particular one speciﬁc
miRNA, miR-133a, clearly correlates with muscle strength measure-
ment and increased in patients with higher MIRS score, potentially
reﬂecting disease severity [134]. This work is particularly signiﬁcant
since the identiﬁcation of minimally invasive analytical biomarkers for
DM1 and the established potential of circulating miRNAs as prognostic
and diagnostic biomarkers are important to monitor DM1 progression
and the effectiveness of new drug treatments.
Another open question in the ﬁeld of DM is to clarify the
pathomechanisms underlying the phenotypic differences between
DM1 and DM2. Clinical signs in DM1 and DM2 are similar, but there
are some distinguishing features: DM2 is generally less severe and
lacks a prevalent congenital form. This suggests that other cellular and
molecular pathways are involved besides the shared toxic-RNA gain of
function hypothesized. Disease-speciﬁc manifestations may result
from differences in spatial and temporal expression patterns of DMPK
and CNBP genes. Similarly, changes in the expression of neighboring
genes may deﬁne disease-speciﬁc manifestations. Importantly, the
role of CUGBP1 in DM2 is particularly intriguing with contradictory
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for the clinical differences between the twoDM forms is the reduction of
DMPK or ZNF9 protein levels in DM1 and DM2 respectively [3,91,103,
136,137] However Dmpk knockout young mice do not develop a
multisystemic phenotype mimicking myotonic dystrophy [138–140].
On the contrary reduction of CNBP levels is sufﬁcient to produce
multiorgan symptoms resembling those of DM as observed in heterozy-
gous Cnbp+/− knockout mice [141]. Moreover the reduction of CNBP
expression has been reported in DM2 comparedwith non-DM2 individ-
uals, including patients with DM1 thus explaining some of the pheno-
typic disparities between both types of DM [103,135,137].
5. Pathology
The histological features of skeletal muscle biopsy in DM1 and DM2
are very similar, and sufﬁciently characteristic that a diagnosis of DM
can be suggested based on muscle biopsy alone [1,13,142]. In both
diseases, affected muscles show a high number of central nuclei and a
markedly increased variation in ﬁber diameter that commonly ranges
from less than 10 μm to greater than 100 μm. Basophilic regenerating
ﬁbers, splitting ﬁbers, ﬁbrosis and adipose deposition occur in both
diseases to a variable degree depending on the extent of muscle in-
volvement. Ring ﬁnger ﬁbers and sarcoplasmic masses are generally
more frequent in DM1muscle biopsy. However the comparison ofmus-
cle biopsy ﬁndings in classic DM1 with those in DM2 has indicated that
speciﬁc features are present in DM2 muscle biopsy helping the diagno-
sis of DM2. Severely atrophic ﬁbers with pyknotic nuclear clumps simi-
lar in appearance to the severely atrophic ﬁbers in neurogenic atrophy
are frequently found in DM2 biopsy also before the occurrence of mus-
cle weakness. In DM1, nuclear clumps are present in end-stage muscle
biopsy [122] (Fig. 1A,B). A predominant type 2 ﬁber atrophy in contrast
to the type 1 atrophy observed in DM1, has been described in DM2
[142–145] (Fig. 1C,D). Moreover, in DM2 muscle biopsy central nucle-
ation selectively affects type 2 ﬁbers and the atrophic nuclear clumps
express fast myosin isoform (type 2 ﬁber) indicating that DM2 is
predominantly a disease of type 2 myoﬁbers [144] (Fig. 1D).
To date there are no deﬁnitive explanation for the histopathological
alterations observed in DM skeletal muscle. However, it has been dem-
onstrated that the combined effects of misregulated splicing of several
genes involved in calcium regulation and EC coupling, such as RyR1,
SERCA and CaV1.1, may contribute to the muscle degeneration in DM
[146–148].
Classically DM has been considered as neuromuscular diseases and
for many years research on DM has been principally focused onmuscu-
lar aspects. However the interest in the neurological aspects of DM has
increased in the last several years since central nervous system (CNS)
dysfunction is one of the major issue affecting quality of life in DM pa-
tients. Recently several workshops of these studies have been organized
to increase our understanding of CNS pathophysiology [24,149].
Cognitive impairment in DM1 has been clearly established. DM1
patients exhibit changes in personality traits and/or mood disorders
[41,150–153]. Brain involvement in DM2 shows similar cognitive and
behavioral dysfunctions as in DM1, with milder manifestations com-
paredwith DM1 [41,154]. In contrast to DM1, DM2 has not been associ-
ated with developmental abnormalities thus explaining why no mental
retardation similar to that reported in congenital and juvenile forms of
DM1 has been described in DM2 patients.
Brain involvement in myotonic dystrophy types 1 and 2 has been
demonstrated in vivo using different neuroimaging techniques. MRI
studies revealed whitematter lesions and diffuse brain atrophy inmyo-
tonic dystrophy types 1 and 2. White matter lesions located within
anterior temporal lobes represent a characteristic feature in myotonic
dystrophy type 1 [155–158]. A recent comparative study on brain
involvement in myotonic dystrophies reveals a frontal white matter
most prominently affected in both disorders, and temporal lesions
restricted to myotonic dystrophy type 1. Voxel-based morphometryanalyses demonstrated extensive white matter involvement in all cere-
bral lobes, brainstem and corpus callosum in myotonic dystrophy types
1 and 2, while graymatter decrease (cortical areas, thalamus, putamen)
was restricted to myotonic dystrophy type 1. Accordingly, we found
more prominent white matter affection in myotonic dystrophy type 1
than myotonic dystrophy type 2 by diffusion tensor imaging [159]. In
myotonic dystrophy type 1, graymatter reductions have been described
in various cortical regions and recently also in hippocampi and thalami
using voxel-based morphometry (VBM) [154,160]. In DM2 patients
gray matter reduction was present in several cortical regions, including
hippocampi, hypothalami and thalami [154,161].
As observed in skeletal muscle, ribonuclear inclusions of CUG-
containing RNA colocalizing with MBNL1 and MBNL2 proteins have
also been detected in human DM1 brains, particularly in the neuronal
cells of the cerebral cortex, hippocampus, dentate gyrus, thalamus,
substantia nigra, and brain stem tegmentum [99]. Interestingly, focus
formation has also been observed in the brains of transgenic DMSXL
mice bearing more than 1000 CTG repeats [162]. These observations
strongly suggest that a pathomechanism involving RNA gain-of-
function and spliceopathy also occurs in DM brain. Indeed missplicing
of Tau exons 2, 3, 6 and 10 has been reported in DM1 brains [99,163,
164]. Jiang et al. [99] reported, defective splicing of other two important
genes in DM1 brain, amyloid-β precursor protein (APP) gene and N-
methyl-D-aspartate receptor 1 (NMDA-R1) gene. In a recent study
Charizanis and collaborators [82] reported that the major pathological
changes in the DM brain are attributable to MBNL2 more than MBNL1
sequestration by C(C)UGexp RNAs. Indeed while Mbnl2 knockout
mice did not display pronounced muscle pathology, the loss of Mbnl2
resulted in widespread splicing abnormalities in the brain. On the con-
trary Mbnl1 knockout mice showmodest effects on alternative splicing
regulation in the brain [85].
In addition to these changes, DM1 brains show neuroﬁbrillary
degeneration (NFD) made of the intraneuronal aggregation of
hyperphosphorylated Tau proteins [163,165]. A similar tau pathology
in the CNS has been reported in DM2 suggesting a similar physiopatho-
logic process that may contribute to common neurologic features in
patients with DM [166].
Cardiac arrhythmias are amajor cause ofmortality in DM1 andDM2,
cardiac deaths occur with low frequency [36,37,167,168], however, the
molecular mechanisms underlying the cardiac defects, are unclear. The
misregulation of miR-1 in heart samples from people with DM1 and
DM2 has been recently reported and it may contribute to the cardiac
dysfunctions observed in affected persons. The signiﬁcant reduction in
the expression of miR-1 in DM heart samples leads to a deregulation
of two important mir-1 targets, GJA1 (connexion 43) and CACNA1C
(cardiac L-type calcium channel). Importantly, the down regulation of
miR-1 in cardiac muscle is caused by MBNL1 nuclear sequestration
since MBNL1 is a cytoplasmic regulator of the biogenesis of pre-miR-1
[133].
More recently, an association between DM1 or DM2 and Brugada
ECG pattern has been reported potential role of Brugada syndrome in
ventricular tachyarrhythmias and sudden death in DM1 patients [169,
170]. Ventricular myocardial specimen analysis displayed a splicing
switch of SCN5A adult exon 6B toward fetal exon 6A [170,171].
Electro-physiological experiments demonstrate that SCN5A channel
containing exon 6A (theDM isoform) presents a slower cardiac conduc-
tion compared to the control SCN5A containing exon 6B [171].6. Animal models
Several importantmousemodels ofmyotonic dystrophies have been
generated to clarify the disease mechanisms however no one model
completely recapitulates all aspects of the multisystemic phenotype in
type 1 or type 2 disease. Here we reviewed the most signiﬁcant
mouse models resulting from the inactivation of genes in the DM1 or
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regulation throughMbnl inactivation or CUGBP1 overexpression.
To test if the reduction of cytoplasmic DMPK transcripts observed in
DM1 had a role in disease pathomechanism, Dmpk or Cnbp/Znf9 knock-
outmice were generated. HoweverDmpk−/−mice failed to reproduce
the complex and multisystemic DM1 phenotype [138,139], suggesting
that haploinsufﬁciency of the gene in the DM1 locus is not the primary
mechanism of disease. On the contrary, Zfn9+/−mice exhibited myo-
tonia, muscle wasting, defective walking, cardiac conduction defects
and ocular cataracts without the alteration of alternative splicing sug-
gesting a role for CNBP haploinsufﬁciency in DM2 pathology [141]. To
further investigate the role of CNBP in DM2, a Cnbp−/− mice modelFig. 1.A–D. Panel showingmuscle histology inDM1 andDM2. A. Hematoxylin & Eosin stained tr
presentwith numerous atrophicﬁbers (arrow) and central nuclei (asterisk). Originalmagniﬁcat
size variation and central nuclei (asterisk) are present. Arrowhead indicates a nuclear clump.
biopsy. The population of atrophic ﬁbers (dark brown) is preferentially type 1 ﬁbers (arrows)
biopsy. Type 2 ﬁbers (dark brown) are predominantly affected in DM2 muscle: type 2 fast pos
magniﬁcation, 200×. E–G. Fluorescence in situ hybridization (FISH) in combination withMBNL
onmuscle section by FISH using (CAGG)5 speciﬁc probe. Red spots represent ribonuclear inclus
inclusions colocalizing with MBNL1 foci in myonuclei (blue, DAPI).has been recently developed. This model shows some features consis-
tent with DM2, including mild myopathy and muscle weakness and
no missplicing thus strengthening the role for CNBP in disease patho-
genesis. Further the characterization of Cnbp−/−mice as a model for
DM2 is under way [172].
The toxicity of expanded transcriptswas studiedwith the generation
of transgenicmice overexpressing untranslated CUG repeats in the skel-
etal muscle. HSALR (long repeat length) model is a transgenic mouse
based on the human skeletal actin (HSA) gene that includes approxi-
mately 250 untranslated CUG repeats [173]. These animals show
MBNL1 sequestration in nuclear foci and the alteration of alternative
splicing of several genes (e.g. Clcn1, Atp2a1/Serca1, Mbnl1, Ldb3/Cypher).ansversal sections of DM1muscle biopsy presenting a severe ﬁbrosis. Fiber size variation is
ion, 200×. B.Hematoxylin & Eosin stained transversal sections of DM2muscle biopsy. Fiber
Original magniﬁcation, 200×. C. Slow myosin (MHCslow) stained section of DM1 muscle
. Original magniﬁcation, 200×. D. Fast myosin (MHCFast) stained section of DM2 muscle
itive nuclear clumps (arrowhead) and type 2 atrophic ﬁbers (arrow) are present. Original
1-immunoﬂuorescence on DM2muscle biopsy. E. Visualization of (CCUG)-containing RNA
ions. F. Visualization of nuclear foci of MBNL1 (green spots). G. Visualization of ribonuclear
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and their myotonia claimed to be sufﬁciently explained by signiﬁcant
reductions in the ClC-1 current. Moreover, these mice present histolog-
ical signs of myopathy but no muscle weakness or wasting and to date
represent the most suitable mouse model to investigate the adult
skeletal muscle pathology.
DM300 mice carrying a large (CTG) 300–600 expansion in the con-
text of the human DM1 locus [174] showed ribonuclear foci in multiple
tissues (e.g. skeletal muscle, heart and CNS), muscle histopathology,
myotonia, progressive muscle weakness, defects in glucose metabolism
due to INSR splicing alteration, growth retardation and high mortality
[175–177]. The intergenerational instability of DM300 led to DMSXL
mice carrying 1000–1800 CTG repeats which exhibit a more severe
phenotype and could represent a model of congenital DM1 [178].
Micemodels have been generated to characterize themolecular and
physiological effects of MBNLs inactivation and CUGBP1 upregulation
and to demonstrate the central role of these two families of splicing
regulators in DM1 pathogenesis.
In Mbnl1Δ3/Δ3 mice disruption of MBNL1 exon 3 eliminates CUG-
binding isoforms andmimics theMBNL1 sequestration and inactivation
observed in DM1 [76]. These mice exhibit overt myotonia associated
with abnormal CLCN1 splicing and develop cataracts and myopathy
but no signs of muscle degeneration [76,100,179]. Recently Suenaga
and collaborators [85] have found three novel splicing events (Sorbs1
exon 25 (exon 26 in human), Dclk1 exon 19 and Camk2d exons
14–16 (exons 14–15 in human)), altered both in DM1 and in Mbnl1-
knockout brains.
To elucidate the role of MBNL2, two knockout lines were generated
however contradictory results were obtained on skeletal muscle.
While myopathy and myotonia associated with CLCN1 splicing alter-
ation were detected in one line [180], the other line appeared to be
overtly normal [100]. To address this inconsistency, a Mbnl2ΔE2/ΔE2
knockout mouse has been generated in which, as Mbnl1 exon 3,
Mbnl2 exon 2 encodes the initiation codon for the full-length Mbnl2
protein [82]. These mice do not display pronounced muscle pathology
and myotonia is absent, however the loss of Mbnl2 results in wide-
spread splicing abnormalities in the brain.
Mbnl1 and Mbnl2 isoform knockout mice recapitulate multiple fea-
tures of adult-onset DM supporting the toxic RNA pathogenetic model.
Moreover, it appears that while MBNL1 regulates alternative splicing
during postnatal development prevalently in muscle, MBNL2 exerts its
function in the brain.
Mbnl3ΔE2/ΔE2 isoform knockout mice have been recently generated
using a homologous recombination strategy previously described for
Mbnl1Δ3/Δ3 and Mbnl2ΔE2/ΔE2. MBNL3 is an unusual member of the
Mbnl family because it is expressed during the embryonic period and
MBNL3 RNA is either absent or detectable only at low levels in adult
tissues [84] indicating that it may not be essential in adults but may
be required during embryogenesis and its sequestration by toxic C(C)
UG-RNAs during embryogenesis might inﬂuence tissue development
in DM1 and DM2. Mbnl3 mice fail to develop overt mutant muscle or
CNS phenotypes during postnatal development but instead show a
late-onset and age-associated impairment of muscle regeneration
following injury. These ﬁndings indicate that MBNL3 expression is im-
portant for normal adult muscle satellite cell activation and/ormyoblast
function [88].
Two CUGBP1-overexpressing lines have been generated to investi-
gate the contribution of CUGBP1 upregulation to DM1 pathogenesis.
The CUGBP1-TR line showed growth retardation, delayed myogenesis,
and histological and molecular abnormalities [118] while the
MCKCUGBP1 mice had normally sized stillborn pups showing histolog-
ical abnormalities and missplicing in skeletal muscle [181]. However,
both lines were characterized by high mortality and breeding difﬁcul-
ties. Subsequently, tissue-speciﬁc CUGBP1 overexpression in either
skeletal muscle or heart of adult mice induced DM1-characteristic phe-
notypes indicating that CUGBP1 upregulation is sufﬁcient to reproducealternative splicing deregulation, myopathy and cardiomyopathy) [182,
183].
7. Diagnosis
As for all genetic diseases with identiﬁed mutation, the typical DM1
and DM2 diagnostic method is mutation veriﬁcation by genetic tests. In
the case of DM1, symptoms and family history are often clear and
distinctive enough to make a clinical diagnosis, and the mutation can
be conﬁrmed by PCR and Southern Blot analysis. PCR analysis is used
to detect repeat lengths less than 100 and Southern blot analysis to
detect larger expansions. Predictive testing in asymptomatic relatives
as well as prenatal and preimplantation diagnosis can also be per-
formed. Recently, a molecular diagnostic kit, Myotonic Dystrophy SB
kit, has been developed and validated. The advantage of this assay is
that all reagents are pre-packaged and ready to use. The analytical re-
sults, evaluated on a total of 113 DNA samples, in terms of sensitivity,
speciﬁcity and accuracy were very high (N99%), and both prospective
and retrospective analyses gave no false positives or false negatives
[184].
Triplet-repeat primed PCR (TP-PCR) [185] has come into routine di-
agnostic procedure since it represents a robust and reliable PCRmethod
that can rapidly identify the presence of expanded alleles for any disor-
der caused by repeat expansions. Although it can distinguish between
healthy homozygous and affected heterozygous sampleswith no length
restriction, it is not able to determine the exact size of the repeats over a
certain threshold. Thus the association of two molecular methods as a
Long-PCR and Southern transfer, together with TP-PCR [186,187], is
strongly recommended because they should be able to detect a wide
range of mutations. Critically, recent evidence has shown that TP-PCR
can lead to false negative results in 3%–5% of DM-1 cases due to
sequence interruptions (comprising CCG, CTG, and GGC sequences)
that lie within the 3′ end of an expanded CTG repeat tract [55]. In
order to address this problem, Radvansky et al. [188] has described a
bidirectionally labeled TP-PCR method in which ampliﬁcation products
are anchored at the 3′ end of a CTG repeat expansion rather than the 5′
end. The effect of this redesign is that it overcomes the failure in detect-
ing expansion-positive patients carrying repeat interruptions.
On the contrary, the wide clinical spectrum DM2 phenotype makes
the clinical diagnosis more difﬁcult. Moreover conventional PCR and
Southern blot analysis are not adequate for a deﬁnitive molecular diag-
nosis in DM2 due to the extremely large size and somatic instability of
the expansion mutation [10,62]. The copy number of DM2 CCTG is
below 30 in phenotypically normal individuals and up 11.000 in
patients [189]. A complex genotyping diagnostic procedure is now com-
monly used consisting of a three step molecular protocol [13,27]: (1) a
conventional PCR assay across the mutation locus using probes binding
to mutation ﬂanking sequences can be used for mutation exclusion. In
all DM2 patients, a single PCR product representing the normal allele
can be identiﬁed because the DNA polymerase fail to amplify the mu-
tant allele due to length and stable secondary structure. All individuals
showing two alleles for the marker are excluded from having the DM2
mutation. However, identical allele size on two normal alleles occurs in
12% of the population; (2) all patients appearing to have one allele
need further molecular analysis to determine whether or not they carry
a DM2 expansion. Because of the incomplete sensitivity of Southern
analysis, a DM2 repeat assay (RP-PCR) was developed; (3) the RP-PCR
method involves amplifying the CCTG repeat by PCR, and probing the
resultant product with an internal probe to assure speciﬁcity. The com-
bined use of these methods allows 99% sensitivity and speciﬁcity for
known expansions. Several alternative and highly sensitive methods
have been developed for DM2 mutation veriﬁcation including long-
range PCR [190] and a tetraplet-primed PCR [187]. A modiﬁed Southern
method using ﬁeld-inversion electrophoresis (FIGE) is particularly efﬁ-
cient in determining the mutation length [62]. However, these methods
are still too long and complicated to be part of routine laboratory
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present before any histological abnormality manifestations [42,191].
This could be important for an early diagnosis before the spectrum of
clinical signs of muscle disease appears. So a more practical tool to ob-
tain a deﬁnitiveDM2diagnosis in fewhours is represented by in situ hy-
bridization (ISH) which is a method that allows the direct visualization
of themutant RNA onmuscle biopsy [192,193]. By using speciﬁc probes
for CCUG expansions, it permits a differential diagnosis between DM2
and DM1. Therefore it may be a simple approach for DM2 diagnosis,
which can be performed in a rapid and sensitive manner in any pathol-
ogy laboratory. ISH with CAGG probe should be considered as a routine
laboratory procedure to conﬁrm or refute the clinical suspicion of DM2.
It should also be applied routinely to screen patients with myotonic
disorders [192,193]. This approach makes muscle biopsy an essential
tool for DM2 diagnosis (Fig. 1E). Moreover, since MBNL1 is sequestered
by mutant RNA foci, it is possible to visualize the nuclear accumulation
of MBNL1 by immunoﬂuorescence on muscle sections (Fig. 1E–G).
However, although MBNL1 represents a histopathological marker of
DM, it does not allow to distinguish between DM1 and DM2 [194].
8. Management
Even though there is currently no cure formyotonic dystrophies, the
activemanagement of patients involvesmonitoring expected complica-
tions of the disease. The management of DM2 is similar to that of DM1
and there are very few speciﬁc treatments that are distinct for DM2. Es-
pecially for DM1, physiatrists can help affected individuals regarding
the need for ankle–foot orthoses, wheelchairs, or other assistive devices
as the disease progresses. Cataracts require monitoring and can be
removed if patients complain impaired vision [23]. Cardiorespiratory
disorders are responsible for 70% of the mortality in DM1 and many
of these patients could have been treated by active monitoring and
a lower threshold for input. Cardiac problems appear to be less
severe and frequent in patients with DM2 than in patients with DM1
[34–36], however, sudden death, pacemaker implantation, and severe
cardiac arrhythmias have been described in small numbers of patients
[31,36,37]. Careful cardiac evaluation is recommended in DM2 patient
population to identify patients at risk for potential major cardiac
arrhythmias [36]. Patients with DM1 frequently report complaints of
daytime sleepiness and/or fatigue that impinge signiﬁcantly on their
quality of life. Early recognition and treatment of sleep-related disor-
dered breathing with nocturnal non-invasive mechanical ventilation
are ﬁrst mandatory. However, daytime sleepiness often persists
and may require a psychostimulant but no consensus has been yet
established [195]. Hypogonadism and insulin resistance need monitor-
ing in both diseases. Insulin resistance is common in people with DM1
and is thought to affect approximately 20% of those with DM2. The
phenomenon should be monitored by a physician and if it becomes
problematic, insulin or other medications that lower blood sugar can
be prescribed. Myotonia tends to be less marked and less troublesome
in DM2, but in speciﬁc circumstances antimyotonia therapy is helpful,
especially if muscle stiffness is frequent and persistent or if pain is
prominent [196]. Some individuals have responded to mexiletine or
carbamazepine. Logigian et al. [197] found mexiletine of 150–200 mg
TID to be effective and safe for treating myotonia. Cognitive difﬁculties
also occur in DM2 as in DM1 but have manifested in adult life and
appear to be associated with decreased cerebral blood ﬂow to frontal
and anterior temporal lobes [38,153] and decreased brain volume
[198,199]. The changes are less severe in DM2 than in DM1. Their etiol-
ogy is unknown but may relate to the toxic effect of intranuclear accu-
mulations of abnormally expanded RNA. The management of these
brain symptoms is similar in DM1 and DM2. Pain in the skeletalmuscles
is a common feature of DM2 and is less common in DM1 [28,33]. The
exact mechanism underlying the pain is unknown, and there is no
well-established, effective treatment. The pain does not appear to be
related to myotonia or to exercise, however cold temperatures make itworse. Painful stiffness can occur, particularly in the legs. Pain manage-
ment can be an important part of DM treatment. Different medications
and combinations of medications work for some individuals, although
none has been routinely effective; medications that have been used
include mexiletine, gabapentin, nonsteroidal anti-inﬂammatory drugs
(NSAIDs), low-dose thyroid replacement, low-dose steroids, and tricy-
clic antidepressants.
9. Conclusions
Currentlymyotonic dystrophies have to be considered also as a brain
disorder in addition to their classic categorization as a muscle disease.
The knowledge of underlying molecular pathomechanism in muscle
and CNS dysfunction inmyotonic dystrophies will be necessary to iden-
tify suitable targets and evaluate therapeutic beneﬁt of current and
future drug candidates.
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